| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Pulmonx (NASDAQ:LUNG) lowers FY2025 sales outlook from $90.000 million-$92.000 million to $89.000 million-$90.000 million vs $9...
Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.42) by 19...
Lake Street analyst Frank Takkinen maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $8 to $4.